Search
Semaglutide Treatment Options
A collection of 194 research studies where Semaglutide is the interventional treatment. These studies are located in the United States . Semaglutide is used for conditions such as Diabetes Mellitus, Type 2, Obesity and Diabetes.
145 - 156 of 194
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes
Withdrawn
This study compares the medicines semaglutide with empagliflozin or metformin in people with newly diagnosed type 2 diabetes. This study will look mainly at how well participant's blood sugar and body weight are controlled when they are taking the study medicines. Participants will either get semaglutide tablets, empagliflozin tablets or metformin tablets. Which treatment participants will get is decided by chance. Currently, doses of 3 milligram (mg), 7 mg and 14 mg semaglutide tablets (Rybelsu... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
02/23/2024
Locations: Hillcrest Family Health Center, Waco, Texas +100 locations
Conditions: Diabetes Mellitus, Type 2
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
Terminated
This randomized study evaluates the effect of subcutaneous semaglutide /in combination with lifestyle counseling in patients with type 2 diabetes mellitus (T2DM), overweight/obesity, and stage 4-5 chronic kidney disease (CKD) or dialysis-dependent end-stage kidney disease (ESKD) on patients' eligibility for kidney transplantation at the end of 9 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: Geisinger Medical Center, Danville, Pennsylvania +1 locations
Conditions: CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity, Severe Obesity
Treating PCOS With Semaglutide vs Active Lifestyle Intervention
Active Not Recruiting
Girls with obesity and polycystic ovarian syndrome will receive either glucagon like peptide-1 receptor agonist therapy or a dietary intervention for 12 weeks to decrease the metabolic syndrome, in particular to lower hepatic fat and improve insulin sensitivity.
Gender:
FEMALE
Ages:
Between 12 years and 21 years
Trial Updated:
01/25/2024
Locations: University of Colorado Anshutz Medical Campus/Children's Hospital Colorado, Aurora, Colorado
Conditions: PCOS, Adolescent Obesity, NAFLD
A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity
Completed
This study will look at the change in teenagers' body weight from the start to the end of the study. This is to compare the effect on body weight in teenagers taking semaglutide (a new medicine) and teenagers taking "dummy" medicine. The teenagers in the study and their parents will also have talks with study staff about healthy food choices, how to be more physically active and what they can do to help the teenagers lose weight. The teenagers will either get semaglutide or "dummy" medicine - wh... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
12/29/2023
Locations: Novo Nordisk Investigational Site, Meridian, Idaho +36 locations
Conditions: Overweight, Obesity
Treatment of GLP-1 for Diabetic Bariatric Patients
Terminated
This study is for patients that are diabetic, and require insulin for glycemic control, and going through the bariatric surgery process. This is a prospective study that is trying to determine if the introduction of a semaglutide increases the remission rates of diabetes post-operatively.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/31/2023
Locations: Geisinger Medical Center, Danville, Pennsylvania
Conditions: Diabetes Mellitus, Type 2
A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)
Completed
The principal goal of this study is to determine the efficacy of efinopegdutide in liver fat reduction in participants with NAFLD. The primary hypotheses are that efinopegdutide is superior to semaglutide, or that efinopegdutide is superior to semaglutide by at least 10% with respect to mean relative reduction from baseline in liver fat content (LFC) after 24 weeks.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
10/25/2023
Locations: Catalina Research Institute, LLC ( Site 1939), Montclair, California +68 locations
Conditions: Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Semaglutide Treatment On Coronary Progression
Completed
The purpose of this research study is to see the effect of the diabetes medicine Semaglutide on a condition called atherosclerosis. Atherosclerosis is a narrowing, blockage, or hardening of the arteries due to a build up of calcium. This study will look specifically at the arteries involving the heart.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
10/03/2023
Locations: Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, Torrance, California
Conditions: Type 2 Diabetes, Coronary Artery Disease
Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM
Recruiting
Conduct a community intervention study that will 1) validate a screening approach to identify patients at risk for advanced NAFLD in the obese or T2DM population, and 2) test whether semaglutide treatment is effective for the management of significant fibrosis due to NAFLD in high-risk patients.
Gender:
ALL
Ages:
Between 40 years and 79 years
Trial Updated:
09/01/2023
Locations: University of California, San Diego, La Jolla, California
Conditions: Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese, Non-Alcoholic Fatty Liver Disease
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors
Active Not Recruiting
This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/17/2023
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Diabetes
Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
Completed
This study will look at the change in body weight from the start to the end of the study. Researchers will compare the weight loss in people taking semaglutide (a new medicine) to people taking "dummy" medicine. In addition to taking the medicine, participants will also have talks with study staff about healthy food choices, how the participant can be more physically active and what participants can do to lose weight. Participants will either get semaglutide or "dummy" medicine - which treatment... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/05/2023
Locations: Novo Nordisk Investigational Site, Birmingham, Alabama +40 locations
Conditions: Overweight, Obesity
Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care
Terminated
Researchers at Sansum Diabetes Research Institute want to learn more about how taking a new approved drug called oral Semaglutide, while eating fresh vegetables, impacts health in Hispanic/Latino adults with type 2 diabetes. This study drug is approved by the United States Food and Drug Administration and may be available by prescription for type 2 diabetes. To do this, 100 Hispanic/Latino adults who have type 2 diabetes will be split into two groups. Over one year, one group will take Semagluti... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2023
Locations: Sansum Diabetes Research Institute, Santa Barbara, California
Conditions: Diabetes Mellitus, Type 2, Glucose Metabolism Disorders (Including Diabetes Mellitus)
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
Completed
This study will look at participants' body weight from the start to the end of the study. The study will last for about 1½ years. This is to compare the effect on body weight in people taking semaglutide once a week or people taking liraglutide once every day. Participants will either get semaglutide, liraglutide or "dummy" medicine. Which treatment is decided by chance. Participants who receive semaglutide or semaglutide "dummy" medicine will need to take 1 injection once a week. Participants w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/18/2023
Locations: Novo Nordisk Investigational Site, Birmingham, Alabama +18 locations
Conditions: Overweight, Obesity
145 - 156 of 194